• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novartis - Articles and news items

ankylosing-spondylitis

NICE recommends Novartis’ ankylosing spondylitis drug

Industry news / 29 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy…

expanded-novartis

Expanded use for Novartis’ Periodic Fever Syndrome drug after 3 new FDA approvals

Industry news / 27 September 2016 / Niamh Louise Marriott, Digital Content Producer

The expanded use is for Ilaris, a selective, high-affinity, human monoclonal antibody that inhibits Interleukin-1 (IL-1) beta, part of the immune system…

progression-ms

Novartis’ long term RRMS drug limits disease progression

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression…

biosimilar-disease-drug

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

ofatumumab-genmab

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

SPMS endpoint novartis

Novartis’ phase III MS study successfully meets endpoints

Industry news / 25 August 2016 / Novartis

The study included 1,651 people with SPMS randomised to receive either 2mg BAF312 or placebo in a 2:1 ratio respectively, the primary endpoint being an improvement in the time to three-month confirmed disability progression, as measured by the expanded disability status scale (EDSS), versus placebo…

cost effective cancer drug

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

New draft guidance advises that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective…

smc

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

psoriasis

Psoriasis survey reveals discrimination and low treatment expectations

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination…

bispecific antibodies

Novartis and Xencor enter bispecific antibody collaboration

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies…

nice

NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…

KAF156

Novartis and MMV expand partnership to develop KAF156

Industry news / 15 June 2016 / Victoria White, Digital Content Producer

Novartis’ KAF156 is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +